Estrogen Receptor Positive Breast Cancer, Invasive Breast Cancer
Conditions
Keywords
breast density change, endocrine therapy response, aromatase inhibitor
Brief summary
Breast density change after short term use of aromatase inhibitor in postmenopausal ER positive breast cancer would predict endocrine responsiveness
Detailed description
Inclusion criteria ER positive breast cancer Postmenopause women Older than 60yr S/P bilateral salphingo-oophorectomy No menstruation history within 1yr and FSH\>30mIU/mL Ipsilateral invasive breast cancer Undergone curative resection No evidence of distant metastasis Capable of breast MRI
Interventions
None listed
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
No minimum to 70 Years
Healthy volunteers
No
Inclusion criteria
* ER positive invasive breast cancer Postmenopause women age 60yrs or older s/p bilateral salphingo-oophorectomy No history of menstruation and FSH\>30mIU Planned for aromatase inhibitor Unilateral breast cancer Curative resection No evidence of distant metastasis
Exclusion criteria
* Bilateral breast cancer Male breast cancer Acceptable for breast MRI Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease free survival | 5 year | recurrence locoregional distant metastasis Confirmed by clinical imaging or pathology |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| breast density change | 6mos, 1yr, 2yr | breast density change measured by cumulus(mammogram) and MRI(bilateral breast MRI) imagings taken after 6mos, 1yr, 2yr after endocrine therapy initiation |
Other
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 5 year | disease specific survival overall survival during 5yr follow up |
Countries
South Korea
Outcome results
None listed